Heart failure & cardiomyopathiesSecondary analysis
Insulin-Like Growth Factor Binding Protein-7 Concentrations in Chronic Heart Failure: Results from the EMPEROR Programme
- Secondary analysis of the EMPEROR-Reduced and EMPEROR-Preserved randomised trials
- biomarker substudy
Authors' conclusion
Across the entire left ventricular EF spectrum in the EMPEROR Programme, concentrations of the senescence-associated biomarker IGFBP7 were associated with higher risk clinical status and predicted adverse cardio-renal outcomes even in models adjusted for conventional biomarkers. Empagliflozin did not significantly affect IGFBP7 levels over time.
Study context
- Population
- Patients with chronic heart failure (HF) across the full ejection fraction (EF) spectrum (EMPEROR-Reduced and EMPEROR-Preserved)
- Participants
- 1,125 patients
- Comparison
- Highest vs lower IGFBP7 tertiles; empagliflozin vs placebo by IGFBP7 tertile
- Primary endpoint
- HF hospitalization or CV death; renal composite endpoint
Primary result
As reported in the abstract
Highest IGFBP7 tertileHazard ratio (95% CI)P value
HF hospitalization or CV death; p for trend <0.001
2.00(1.28–3.10)
P = 0.002renal composite endpoint; p for trend = 0.001
4.66(1.61–13.53)
P = 0.005Further findings
Effect of empagliflozin on CV death/HF hospitalization by baseline IGFBP7 tertile
- Empagliflozin reduced risk irrespective of baseline IGFBP7
- p for trend across IGFBP7 tertiles = 0.26
Change in IGFBP7 with empagliflozin · 12 or 52 weeks
- No meaningful change in IGFBP7 with empagliflozin
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Insulin-Like Growth Factor Binding Protein-7 Concentrations in Chronic Heart Failure: Results from the EMPEROR Programme. Eur J Heart Fail. Published 8 April 2024. doi:10.1002/ejhf.3227
Summarised from the published abstract; every number is checked against it